- ►diabetesjournals.org DJ Drucker - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic
peptide (GIP) exert important effects on β-cells to stimulate glucose-dependent
insulin secretion. Both peptides also regulate β-cell proliferation and ... Cited by 283 - Related articles - All 13 versions
- ►endojournals.org PL Brubaker, DJ Drucker - Endocrinology, 2004 - Endocrine Soc Gut peptides exert diverse effects regulating satiety, gastrointestinal motility
and acid secretion, epithelial integrity, and both nutrient absorption and
disposal. These actions are initiated by activation of specific G protein- ... Cited by 216 - Related articles - BL Direct - All 7 versions
LL Nielsen, AA Young, DG Parkes - Regulatory peptides, 2004 - Elsevier Exenatide (synthetic exendin-4), glucagon-like peptide-1 (GLP-1), and GLP-1
analogues have actions with the potential to significantly improve glycemic
control in patients with diabetes. Evidence suggests that these agents use ... Cited by 185 - Related articles - All 7 versions
- ►ubc.ca [PDF] PD Gluckman, MA Hanson - Trends in Endocrinology & Metabolism, 2004 - Elsevier Both epidemiological and clinical evidence suggest relationships between the
antenatal environment and the risk of developing insulin resistance and
associated cardiovascular disease (part of the metabolic syndrome) in ... Cited by 159 - Related articles - All 7 versions
- ►diabetesjournals.org CF Deacon - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 is an incretin hormone with potent
glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on
the pancreatic β-cells, and inhibitory effects on gastrointestinal ... Cited by 154 - Related articles - BL Direct - All 5 versions
- ►physiology.org JJ Holst - Physiological reviews, 2007 - Am Physiological Soc Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in
the intestinal epithelial endocrine L-cells by differential processing of
proglucagon, the gene which is expressed in these cells. The current ... Cited by 113 - Related articles - BL Direct - All 5 versions
- ►endojournals.org DJ Drucker - Endocrinology, 2003 - Endocrine Soc Studies of the natural history of type 2 diabetes inform us that a progressive
decline in ß-cell function is common in diabetic patients independent of the
method of treatment (2). Hence, new approaches are clearly needed that not ... Cited by 101 - Related articles - BL Direct - All 4 versions
- ►endojournals.org BR Gedulin, SE Nikoulina, PA Smith, G … - Endocrinology, 2005 - Endocrine Soc The effects of the incretin mimetic exenatide (exendin-4) on metabolic
parameters, insulin sensitivity, and ß-cell mass were examined in nondiabetic,
insulin-resistant obese fa/fa Zucker rats. After 6 wk of treatment, ad ... Cited by 98 - Related articles - All 5 versions
PD Gluckman, MA Hanson, AS Beedle - American Journal of Human Biology, 2007 - pinniped.net PETER D. GLUCKMAN,1,2* MARK A. HANSON,2 AND ALAN S. BEEDLE1 1Liggins Institute,
University of Auckland, and National Research Centre for Growth and Development,
Private Bag 92019, Auckland, New Zealand 2Centre for Developmental Origins ... Cited by 88 - Related articles - View as HTML - BL Direct - All 6 versions
- ►tufts.edu [PDF] LL Baggio, DJ Drucker, 2006 - Annual Reviews Type 2 diabetes is characterized by hyperglycemia resulting from insulin
resistance in the setting of inadequate β-cell compensation. Currently
available therapeutic agents lower blood glucose through multiple ... Cited by 77 - Related articles - BL Direct - All 10 versions
